Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer
Joint Authors
Wang, Di
Che, Yi-Qun
Men, Yu
Hui, Zhouguang
Kang, Jingjing
Luo, Yang
Wang, Jianyang
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-04-30
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
This study is aimed at investigating the prognostic biomarkers of patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC) and at analyzing the correlation between tumor mutation load (the frequency and number of tumor mutations) and prognosis.
Clinical data of 35 patients with stage IIIA-N2 NSCLC were collected from Cancer Hospital, Chinese Academy of Medical Sciences.
Whole blood samples from the peripheral vein were taken at different treatment periods, and the mutations of cell-free DNA (cfDNA) were detected.
Multivariate analysis showed that smoking (P=0.0308), mutation number>2 (P=0.0283), and max mutation frequency>0.025 (P=0.0450) were associated with improved progression-free survival (PFS).
The overall survival (OS) of well-differentiated NSCLC patients was better than that of poorly differentiated ones (P=0.0006).
The rates of PFS, disease-free survival, local-regional recurrence-free survival, and local-regional progression-free survival were significantly higher in the group with a mutation number>2 than in the group with a mutation number≤2.
The mutation number of the preoperation group was significantly higher than that of the postradiochemotherapy group (5 vs.
2.5, P=0.023), and the max mutation frequency change was approximately significant in the postradiochemotherapy group compared with the postoperation group (2.6% vs.
1.85%, P=0.067).
The max mutation frequency is positively correlated with vascular invasion (21.13% vs.
3.62%, P=0.04).
Furthermore, Met, ALK, APC, PTEN, ERBB4, NF1, and other genes, involving multiple tumor suppressor genes and lung cancer-driven genes, did not mutate in recurrence-free patients when compared with recurrent patients.
In conclusion, differentiation, smoking, mutation frequency>0.025, and mutation number>2 are prognostic factors.
The frequency and number of gene mutations in cfDNA are expected to be prognostic predictors of NSCLC.
American Psychological Association (APA)
Kang, Jingjing& Luo, Yang& Wang, Di& Men, Yu& Wang, Jianyang& Che, Yi-Qun…[et al.]. 2019. Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. Disease Markers،Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1147109
Modern Language Association (MLA)
Kang, Jingjing…[et al.]. Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. Disease Markers No. 2019 (2019), pp.1-10.
https://search.emarefa.net/detail/BIM-1147109
American Medical Association (AMA)
Kang, Jingjing& Luo, Yang& Wang, Di& Men, Yu& Wang, Jianyang& Che, Yi-Qun…[et al.]. Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1147109
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147109